Cancer: Medical Treatments

(asked on 2nd September 2024) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many myeloma patients are receiving a fourth line treatment; and what proportion of those patients are being treated with isatuximab in combination with pomalidomide and dexamethasone.


Answered by
Karin Smyth Portrait
Karin Smyth
Minister of State (Department of Health and Social Care)
This question was answered on 11th September 2024

Information on the number of myeloma patients receiving a fourth line treatment is not held centrally. However, the following table shows the number of patients notified to receive isatuximab, in combination with pomalidomide and dexamethasone, in 2021, 2022, 2023 and from January to July of 2024:

2021

2022

2023

2024

Patients notified to receive isatuximab, pomalidomide, and dexamethasone

508

522

464

278

Source: NHS England.
Note: not all patients will necessarily go on to receive the treatment itself.

Reticulating Splines